nodes	percent_of_prediction	percent_of_DWPC	metapath
Pranlukast—TNF—osteoporosis	0.489	1	CbGaD
Pranlukast—ABCC2—Ethinyl Estradiol—osteoporosis	0.0813	0.227	CbGbCtD
Pranlukast—ABCC2—Conjugated Estrogens—osteoporosis	0.0596	0.166	CbGbCtD
Pranlukast—CYP2C9—Estropipate—osteoporosis	0.0424	0.118	CbGbCtD
Pranlukast—CYP3A4—Estropipate—osteoporosis	0.0246	0.0687	CbGbCtD
Pranlukast—CYP3A4—Calcitriol—osteoporosis	0.0246	0.0687	CbGbCtD
Pranlukast—CYP2C9—Cholecalciferol—osteoporosis	0.0218	0.0609	CbGbCtD
Pranlukast—CYP3A4—Ergocalciferol—osteoporosis	0.0197	0.0549	CbGbCtD
Pranlukast—CYP2C9—Estradiol—osteoporosis	0.0176	0.0491	CbGbCtD
Pranlukast—CYP3A4—Raloxifene—osteoporosis	0.0164	0.0458	CbGbCtD
Pranlukast—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0159	0.0443	CbGbCtD
Pranlukast—CYP3A4—Cholecalciferol—osteoporosis	0.0127	0.0354	CbGbCtD
Pranlukast—CYP3A4—Conjugated Estrogens—osteoporosis	0.0116	0.0325	CbGbCtD
Pranlukast—CYP3A4—Estradiol—osteoporosis	0.0102	0.0285	CbGbCtD
Pranlukast—Ospemifene—ESR1—osteoporosis	0.00176	1	CrCbGaD
Pranlukast—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	6.35e-05	0.000422	CbGpPWpGaD
Pranlukast—IL5—Cytokine Signaling in Immune system—IL6—osteoporosis	6.34e-05	0.000422	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—PSMA2—osteoporosis	6.32e-05	0.00042	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—PSMA5—osteoporosis	6.32e-05	0.00042	CbGpPWpGaD
Pranlukast—NFKB1—Toll Like Receptor 9 (TLR9) Cascade—IL6—osteoporosis	6.28e-05	0.000418	CbGpPWpGaD
Pranlukast—NFKB1—TNF alpha Signaling Pathway—IL6—osteoporosis	6.28e-05	0.000418	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—CALCR—osteoporosis	6.25e-05	0.000416	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—PTH1R—osteoporosis	6.25e-05	0.000416	CbGpPWpGaD
Pranlukast—TNF—Folate Metabolism—IL6—osteoporosis	6.24e-05	0.000415	CbGpPWpGaD
Pranlukast—NFKB1—MyD88:Mal cascade initiated on plasma membrane—IL6—osteoporosis	6.17e-05	0.00041	CbGpPWpGaD
Pranlukast—NFKB1—Cytokine Signaling in Immune system—IRS1—osteoporosis	6.16e-05	0.00041	CbGpPWpGaD
Pranlukast—NFKB1—Signaling by NGF—IRS1—osteoporosis	6.06e-05	0.000403	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—ACTG1—osteoporosis	5.97e-05	0.000397	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—P4HB—osteoporosis	5.96e-05	0.000396	CbGpPWpGaD
Pranlukast—NFKB1—MyD88-independent cascade—IL6—osteoporosis	5.92e-05	0.000394	CbGpPWpGaD
Pranlukast—TNF—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	5.9e-05	0.000393	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—CALCA—osteoporosis	5.89e-05	0.000392	CbGpPWpGaD
Pranlukast—TNF—Regulation of toll-like receptor signaling pathway—IL1B—osteoporosis	5.87e-05	0.000391	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—PTH—osteoporosis	5.8e-05	0.000385	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	5.79e-05	0.000385	CbGpPWpGaD
Pranlukast—NFKB1—Cytokine Signaling in Immune system—IL6R—osteoporosis	5.79e-05	0.000385	CbGpPWpGaD
Pranlukast—NFKB1—Toll-like Receptor Signaling Pathway—IL6—osteoporosis	5.78e-05	0.000385	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—KL—osteoporosis	5.77e-05	0.000384	CbGpPWpGaD
Pranlukast—IL5—GPCR downstream signaling—POMC—osteoporosis	5.75e-05	0.000382	CbGpPWpGaD
Pranlukast—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	5.71e-05	0.00038	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—RAP1A—osteoporosis	5.7e-05	0.000379	CbGpPWpGaD
Pranlukast—NFKB1—Signaling by NGF—IL6R—osteoporosis	5.69e-05	0.000378	CbGpPWpGaD
Pranlukast—IL5—Immune System—IRS2—osteoporosis	5.67e-05	0.000377	CbGpPWpGaD
Pranlukast—NFKB1—Senescence-Associated Secretory Phenotype (SASP)—IL6—osteoporosis	5.65e-05	0.000376	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—CNR2—osteoporosis	5.65e-05	0.000376	CbGpPWpGaD
Pranlukast—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	5.65e-05	0.000376	CbGpPWpGaD
Pranlukast—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	5.63e-05	0.000375	CbGpPWpGaD
Pranlukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	5.62e-05	0.000374	CbGpPWpGaD
Pranlukast—NFKB1—Integrated Breast Cancer Pathway—MYC—osteoporosis	5.62e-05	0.000374	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR downstream signaling—ADCY5—osteoporosis	5.61e-05	0.000373	CbGpPWpGaD
Pranlukast—NFKB1—Regulation of toll-like receptor signaling pathway—TNF—osteoporosis	5.59e-05	0.000372	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—NFATC1—osteoporosis	5.56e-05	0.00037	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—KL—osteoporosis	5.54e-05	0.000369	CbGpPWpGaD
Pranlukast—NFKB1—Signaling by Interleukins—IL6—osteoporosis	5.52e-05	0.000367	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—DKK1—osteoporosis	5.51e-05	0.000367	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	5.49e-05	0.000365	CbGpPWpGaD
Pranlukast—TNF—SIDS Susceptibility Pathways—IL1B—osteoporosis	5.36e-05	0.000356	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—KL—osteoporosis	5.35e-05	0.000356	CbGpPWpGaD
Pranlukast—NFKB1—Activated TLR4 signalling—IL6—osteoporosis	5.33e-05	0.000354	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—WNT1—osteoporosis	5.31e-05	0.000353	CbGpPWpGaD
Pranlukast—IL5—Hemostasis—TGFB1—osteoporosis	5.24e-05	0.000349	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—POMC—osteoporosis	5.22e-05	0.000347	CbGpPWpGaD
Pranlukast—TNF—Spinal Cord Injury—MYC—osteoporosis	5.22e-05	0.000347	CbGpPWpGaD
Pranlukast—TNF—Spinal Cord Injury—TGFB1—osteoporosis	5.2e-05	0.000346	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—FGA—osteoporosis	5.17e-05	0.000344	CbGpPWpGaD
Pranlukast—NFKB1—MAPK Signaling Pathway—MYC—osteoporosis	5.16e-05	0.000343	CbGpPWpGaD
Pranlukast—NFKB1—MAPK Signaling Pathway—TGFB1—osteoporosis	5.15e-05	0.000342	CbGpPWpGaD
Pranlukast—CYP2C9—Phase 1 - Functionalization of compounds—POMC—osteoporosis	5.15e-05	0.000342	CbGpPWpGaD
Pranlukast—NFKB1—SIDS Susceptibility Pathways—TNF—osteoporosis	5.1e-05	0.000339	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—ADCY5—osteoporosis	5.09e-05	0.000339	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—IL6R—osteoporosis	5.09e-05	0.000339	CbGpPWpGaD
Pranlukast—TNF—MAPK Signaling Pathway—IL1B—osteoporosis	5.05e-05	0.000336	CbGpPWpGaD
Pranlukast—NFKB1—Toll Like Receptor 4 (TLR4) Cascade—IL6—osteoporosis	5.01e-05	0.000333	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—RAP1A—osteoporosis	4.99e-05	0.000332	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—MGLL—osteoporosis	4.96e-05	0.00033	CbGpPWpGaD
Pranlukast—TNF—Selenium Micronutrient Network—IL6—osteoporosis	4.96e-05	0.00033	CbGpPWpGaD
Pranlukast—IL5—Immune System—IRS1—osteoporosis	4.95e-05	0.000329	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—CTSK—osteoporosis	4.95e-05	0.000329	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—NFATC1—osteoporosis	4.87e-05	0.000324	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—LRP5—osteoporosis	4.85e-05	0.000322	CbGpPWpGaD
Pranlukast—TNF—Adipogenesis—TGFB1—osteoporosis	4.82e-05	0.00032	CbGpPWpGaD
Pranlukast—NFKB1—MAPK Signaling Pathway—TNF—osteoporosis	4.81e-05	0.00032	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—PTHLH—osteoporosis	4.8e-05	0.000319	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—BMP2—osteoporosis	4.8e-05	0.000319	CbGpPWpGaD
Pranlukast—TNF—TNF alpha Signaling Pathway—IL6—osteoporosis	4.79e-05	0.000318	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—FGB—osteoporosis	4.7e-05	0.000313	CbGpPWpGaD
Pranlukast—NFKB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	4.66e-05	0.00031	CbGpPWpGaD
Pranlukast—IL5—Immune System—IL6R—osteoporosis	4.65e-05	0.000309	CbGpPWpGaD
Pranlukast—NFKB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	4.65e-05	0.000309	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—LRP6—osteoporosis	4.63e-05	0.000308	CbGpPWpGaD
Pranlukast—CYP2C9—Biological oxidations—CYP19A1—osteoporosis	4.55e-05	0.000302	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—AGER—osteoporosis	4.54e-05	0.000302	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—PSMA2—osteoporosis	4.54e-05	0.000302	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—PSMA5—osteoporosis	4.54e-05	0.000302	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—ADCY5—osteoporosis	4.52e-05	0.000301	CbGpPWpGaD
Pranlukast—NFKB1—Regulation of toll-like receptor signaling pathway—IL6—osteoporosis	4.51e-05	0.0003	CbGpPWpGaD
Pranlukast—CYP2C9—Metapathway biotransformation—CYP19A1—osteoporosis	4.49e-05	0.000298	CbGpPWpGaD
Pranlukast—NFKB1—Toll-Like Receptors Cascades—IL6—osteoporosis	4.46e-05	0.000297	CbGpPWpGaD
Pranlukast—TNF—Toll-like Receptor Signaling Pathway—IL6—osteoporosis	4.41e-05	0.000293	CbGpPWpGaD
Pranlukast—NFKB1—Cytokine Signaling in Immune system—IL1B—osteoporosis	4.4e-05	0.000293	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—LEP—osteoporosis	4.39e-05	0.000292	CbGpPWpGaD
Pranlukast—NFKB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	4.34e-05	0.000288	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	4.27e-05	0.000284	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—CALCA—osteoporosis	4.23e-05	0.000281	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—ADCY5—osteoporosis	4.19e-05	0.000279	CbGpPWpGaD
Pranlukast—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	4.19e-05	0.000278	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	4.16e-05	0.000277	CbGpPWpGaD
Pranlukast—NFKB1—Myometrial Relaxation and Contraction Pathways—IL6—osteoporosis	4.14e-05	0.000275	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR downstream signaling—POMC—osteoporosis	4.12e-05	0.000274	CbGpPWpGaD
Pranlukast—NFKB1—SIDS Susceptibility Pathways—IL6—osteoporosis	4.12e-05	0.000274	CbGpPWpGaD
Pranlukast—ABCC2—NRF2 pathway—TGFB1—osteoporosis	4.09e-05	0.000272	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—SPP1—osteoporosis	4.06e-05	0.00027	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—PSMA2—osteoporosis	3.97e-05	0.000264	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—PSMA5—osteoporosis	3.97e-05	0.000264	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—IRS2—osteoporosis	3.96e-05	0.000263	CbGpPWpGaD
Pranlukast—TNF—MAPK Signaling Pathway—MYC—osteoporosis	3.93e-05	0.000261	CbGpPWpGaD
Pranlukast—TNF—MAPK Signaling Pathway—TGFB1—osteoporosis	3.92e-05	0.000261	CbGpPWpGaD
Pranlukast—TNF—Spinal Cord Injury—IL6—osteoporosis	3.92e-05	0.000261	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—TLN1—osteoporosis	3.91e-05	0.00026	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—KL—osteoporosis	3.84e-05	0.000255	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—IRS2—osteoporosis	3.8e-05	0.000253	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—POMC—osteoporosis	3.75e-05	0.000249	CbGpPWpGaD
Pranlukast—NFKB1—Fc epsilon receptor (FCERI) signaling—IL6—osteoporosis	3.72e-05	0.000247	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—IL6R—osteoporosis	3.67e-05	0.000244	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—IRS2—osteoporosis	3.67e-05	0.000244	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—IL6R—osteoporosis	3.65e-05	0.000243	CbGpPWpGaD
Pranlukast—TNF—Adipogenesis—IL6—osteoporosis	3.63e-05	0.000241	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—LEP—osteoporosis	3.59e-05	0.000239	CbGpPWpGaD
Pranlukast—NFKB1—Cellular Senescence—IL6—osteoporosis	3.58e-05	0.000238	CbGpPWpGaD
Pranlukast—TNF—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	3.55e-05	0.000236	CbGpPWpGaD
Pranlukast—TNF—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	3.54e-05	0.000235	CbGpPWpGaD
Pranlukast—IL5—Immune System—IL1B—osteoporosis	3.54e-05	0.000235	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—IRS1—osteoporosis	3.45e-05	0.00023	CbGpPWpGaD
Pranlukast—TNF—Regulation of toll-like receptor signaling pathway—IL6—osteoporosis	3.44e-05	0.000229	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—ESR1—osteoporosis	3.43e-05	0.000228	CbGpPWpGaD
Pranlukast—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	3.39e-05	0.000226	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—P4HB—osteoporosis	3.37e-05	0.000224	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—KL—osteoporosis	3.36e-05	0.000224	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—LEP—osteoporosis	3.34e-05	0.000222	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	3.33e-05	0.000221	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—IRS1—osteoporosis	3.32e-05	0.000221	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—PTH—osteoporosis	3.28e-05	0.000218	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—IL6R—osteoporosis	3.25e-05	0.000216	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—RAP1A—osteoporosis	3.23e-05	0.000215	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—IRS1—osteoporosis	3.2e-05	0.000213	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—CNR2—osteoporosis	3.2e-05	0.000213	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—NFATC1—osteoporosis	3.15e-05	0.000209	CbGpPWpGaD
Pranlukast—TNF—SIDS Susceptibility Pathways—IL6—osteoporosis	3.14e-05	0.000209	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—DKK1—osteoporosis	3.12e-05	0.000208	CbGpPWpGaD
Pranlukast—ABCC2—Transmembrane transport of small molecules—ADCY5—osteoporosis	3.09e-05	0.000205	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—POMC—osteoporosis	3.08e-05	0.000205	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—ADCY5—osteoporosis	3.01e-05	0.0002	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—IL6R—osteoporosis	3.01e-05	0.0002	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—WNT1—osteoporosis	3.01e-05	0.0002	CbGpPWpGaD
Pranlukast—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	3e-05	0.000199	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—IGF1—osteoporosis	2.97e-05	0.000197	CbGpPWpGaD
Pranlukast—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	2.96e-05	0.000197	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—FGA—osteoporosis	2.93e-05	0.000195	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—SPP1—osteoporosis	2.91e-05	0.000194	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	2.83e-05	0.000188	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—IL6R—osteoporosis	2.8e-05	0.000186	CbGpPWpGaD
Pranlukast—CYP2C9—Biological oxidations—POMC—osteoporosis	2.73e-05	0.000182	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—PTHLH—osteoporosis	2.72e-05	0.000181	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—BMP2—osteoporosis	2.72e-05	0.000181	CbGpPWpGaD
Pranlukast—NFKB1—Cellular responses to stress—IL6—osteoporosis	2.7e-05	0.00018	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—FGB—osteoporosis	2.66e-05	0.000177	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—AGER—osteoporosis	2.64e-05	0.000176	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—ADCY5—osteoporosis	2.63e-05	0.000175	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—IRS2—osteoporosis	2.63e-05	0.000175	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—PKM—osteoporosis	2.58e-05	0.000171	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—FDPS—osteoporosis	2.58e-05	0.000171	CbGpPWpGaD
Pranlukast—NFKB1—Cytokine Signaling in Immune system—IL6—osteoporosis	2.58e-05	0.000171	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—LEP—osteoporosis	2.58e-05	0.000171	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—PSMA2—osteoporosis	2.57e-05	0.000171	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—PSMA5—osteoporosis	2.57e-05	0.000171	CbGpPWpGaD
Pranlukast—NFKB1—Signaling by NGF—IL6—osteoporosis	2.53e-05	0.000169	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—ESR1—osteoporosis	2.46e-05	0.000164	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—PGLS—osteoporosis	2.44e-05	0.000163	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—GPD2—osteoporosis	2.44e-05	0.000163	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—CALCA—osteoporosis	2.39e-05	0.000159	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—IRS2—osteoporosis	2.31e-05	0.000153	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—IRS1—osteoporosis	2.3e-05	0.000153	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—IL6—osteoporosis	2.27e-05	0.000151	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—ATIC—osteoporosis	2.24e-05	0.000149	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—PNP—osteoporosis	2.24e-05	0.000149	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—POMC—osteoporosis	2.21e-05	0.000147	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—KL—osteoporosis	2.17e-05	0.000145	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—TGFB1—osteoporosis	2.17e-05	0.000144	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—IL6R—osteoporosis	2.16e-05	0.000144	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—IGF1—osteoporosis	2.13e-05	0.000142	CbGpPWpGaD
Pranlukast—IL5—Immune System—IL6—osteoporosis	2.07e-05	0.000138	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—TNF—osteoporosis	2.03e-05	0.000135	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—IRS1—osteoporosis	2.01e-05	0.000134	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—OXCT1—osteoporosis	1.9e-05	0.000126	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—CA2—osteoporosis	1.9e-05	0.000126	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—IL6R—osteoporosis	1.89e-05	0.000126	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—MGLL—osteoporosis	1.85e-05	0.000123	CbGpPWpGaD
Pranlukast—CYP3A4—Biological oxidations—POMC—osteoporosis	1.8e-05	0.00012	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—MYC—osteoporosis	1.78e-05	0.000119	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—TGFB1—osteoporosis	1.78e-05	0.000118	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	1.75e-05	0.000116	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—ADCY5—osteoporosis	1.7e-05	0.000113	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—PKM—osteoporosis	1.7e-05	0.000113	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—FDPS—osteoporosis	1.7e-05	0.000113	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—TGFB1—osteoporosis	1.66e-05	0.00011	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—SPP1—osteoporosis	1.65e-05	0.00011	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—IL6—osteoporosis	1.64e-05	0.000109	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—IL6—osteoporosis	1.63e-05	0.000108	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—PGLS—osteoporosis	1.61e-05	0.000107	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—GPD2—osteoporosis	1.61e-05	0.000107	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—IDH2—osteoporosis	1.58e-05	0.000105	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—IRS2—osteoporosis	1.49e-05	9.91e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—CYP27A1—osteoporosis	1.48e-05	9.85e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—PNP—osteoporosis	1.47e-05	9.8e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—ATIC—osteoporosis	1.47e-05	9.8e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—LEP—osteoporosis	1.46e-05	9.7e-05	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—IL6—osteoporosis	1.45e-05	9.61e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—ACP5—osteoporosis	1.44e-05	9.58e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—IL1B—osteoporosis	1.44e-05	9.56e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.42e-05	9.46e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—ESR1—osteoporosis	1.39e-05	9.26e-05	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—IL6—osteoporosis	1.34e-05	8.91e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—TPI1—osteoporosis	1.34e-05	8.91e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—IRS1—osteoporosis	1.3e-05	8.65e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—MYC—osteoporosis	1.28e-05	8.51e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—TGFB1—osteoporosis	1.28e-05	8.48e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—P4HB—osteoporosis	1.26e-05	8.37e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—CA2—osteoporosis	1.25e-05	8.34e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—OXCT1—osteoporosis	1.25e-05	8.34e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—POMC—osteoporosis	1.25e-05	8.33e-05	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—IL6—osteoporosis	1.25e-05	8.29e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—GAPDH—osteoporosis	1.24e-05	8.22e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—IL6R—osteoporosis	1.22e-05	8.13e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—MGLL—osteoporosis	1.22e-05	8.12e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—IGF1—osteoporosis	1.21e-05	8.01e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—RAP1A—osteoporosis	1.2e-05	8e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.05e-05	6.98e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—IDH2—osteoporosis	1.04e-05	6.91e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—CYP27A1—osteoporosis	9.77e-06	6.49e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—ENO1—osteoporosis	9.73e-06	6.47e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—IL6—osteoporosis	9.62e-06	6.39e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—PSMA5—osteoporosis	9.59e-06	6.38e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—PSMA2—osteoporosis	9.59e-06	6.38e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—ACP5—osteoporosis	9.5e-06	6.32e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—TPI1—osteoporosis	8.83e-06	5.87e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—IL6—osteoporosis	8.42e-06	5.6e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—P4HB—osteoporosis	8.3e-06	5.52e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—GAPDH—osteoporosis	8.15e-06	5.42e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—RAP1A—osteoporosis	7.94e-06	5.28e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—CYP19A1—osteoporosis	7.78e-06	5.17e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—MYC—osteoporosis	7.24e-06	4.82e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—TGFB1—osteoporosis	7.22e-06	4.8e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—ENO1—osteoporosis	6.42e-06	4.27e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—ADCY5—osteoporosis	6.36e-06	4.23e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—GPX1—osteoporosis	6.33e-06	4.21e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—PSMA5—osteoporosis	6.32e-06	4.21e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—PSMA2—osteoporosis	6.32e-06	4.21e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—MTHFR—osteoporosis	5.85e-06	3.89e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—IL6—osteoporosis	5.44e-06	3.62e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—CYP19A1—osteoporosis	5.13e-06	3.41e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—POMC—osteoporosis	4.68e-06	3.11e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—ADCY5—osteoporosis	4.19e-06	2.79e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—GPX1—osteoporosis	4.18e-06	2.78e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—MTHFR—osteoporosis	3.86e-06	2.56e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—POMC—osteoporosis	3.08e-06	2.05e-05	CbGpPWpGaD
